Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project

Hepatology

Volumn 60, Issue 1, 2014, Pages 106-113

  Sampedro, Blanca ^a,b   Hernández López, Cándido ^c,d   Ferrandiz, José Ramón ^a   Illaro, Aitziber ^a   Fábrega, Emilio ^a,e   Cuadrado, Antonio ^a,e   Iruzubieta, Paula ^a,e   Menéndez, Susana ^a,e   Cabezas, Joaquín ^a,e   Crespo, Javier ^a,e,f  

^a Gastroenterology and Hepatology Unit Marqués de Valdecilla University Hospital   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; CETUXIMAB; ETANERCEPT; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; TRASTUZUMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CHILD; COMPUTERIZED PROVIDER ORDER ENTRY; ELECTRONIC PRESCRIBING; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROLOGY; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOLOGICAL FACTORS; CHILD; FEASIBILITY STUDIES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEDICAL ORDER ENTRY SYSTEMS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RISK FACTORS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84903302073     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27103     Document Type: Article

References (43)

1. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49:S156-165.
2. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
3. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012;9:156-166.
4. Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res 2013;43:113-121.
5. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1-20.
6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
7. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007;37:705-712.
8. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
10. Buti M, Garcia-Samaniego J, Prieto M, Rodriguez M, Sanchez-Tapias JM, Suarez E, et al. [Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B infection (2012).] Gastroenterol Hepatol 2012;35:512-528.
11. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934.
12. Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990;8:261-270.
13. Sampedro B, Cabezas J, Menendez S, Ferrandiz JR, Hernandez C, Crespo J. Use of the computer physician order entry (CPOE) system to reduce the risk of hepatitis B virus (HBV) reactivation in patients prior to starting immunosuppressive system [Abstract]. Hepatology 2012;56(Suppl):641A.
14. García-Bengoechea M, Crespo J, Gea F, Zozaya JM, Pons JA, Simón MA, Gómez R, et al. Pre-immunosuppressant hepatitis B virus screening practices among various medical specialties (HEBRA Project): results of a survey from 19 Spanish hospitals [Abstract]. Hepatology 2012;56(Suppl):635A.
15. Eslami S, de Keizer NF, Abu-Hanna A. The impact of computerized physician medication order entry in hospitalized patients-a systematic review. Int J Med Inform 2008;77:365-376.
16. Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. J Am Med Inform Assoc 2008;15:585-580.
17. Zaal RJ, Jansen MM, Duisenberg-van Essenberg M, Tijssen CC, Roukema JA, van den Bemt PM. Identification of drug-related problems by a clinical pharmacist in addition to computerized alerts. Int J Clin Pharm 2013;35:753-762.
18. Liu CY, Chandrasekar PH, Masood A, Schiffer CA. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation. J Oncol Pharm Pract 2013;19:18-23.
19. Aarts J, Koppel R. Implementation of computerized physician order entry in seven countries. Health Aff (Millwood) 2009;28:404-414.
20. Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol 2010;17:32-38
21. Hwang JP, Fisch MJ, Zhang H, Kallen MA, Routbort MJ, Lal LS, et al. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract 2012;8:e32-39.
22. Mendez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, et al. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011;31:330-339.
23. Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, Jiang Y. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. World J Gastroenterol 2013;19:923-930.
24. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, Lopez-Roses L, Brito-Zeron P, Perez-de-Lis M, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 2011;90:359-371.
25. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013;31:118-121.
26. Park SH, Yang SK, Lim YS, Shim JH, Yang DH, Jung KW, et al. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis 2012;18:2004-2010.
27. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996;78:2210-2215.
28. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8:S107-109.
29. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
30. Umemura T, Tanaka E, Kiyosawa K, Kumada H, Japan de novo Hepatitis BRG. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 2008;47:e52-56.
31. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-611.
32. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22:1170-1180.
33. Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, et al. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010;2010:182067.
34. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003;102:1930.
35. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68.
36. Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012;91:1007-1012.
37. Seto W-K CT, Hwang Y, Choi O, Wong D, Fung J, Lie A, Lai C, et al. Interim analysis of hepatitis B reactivation in patients with prior HBV exposure undergoing rituximab-containing chemotherapy: a prospective study [Abstract]. Hepatology 2013;58(Suppl):224A.
38. European Center for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: ECDC. 2010.
39. Alvarez-Suarez B, de la Revilla-Negro J, Ruiz-Antoran B, Calleja-Panero JL. Hepatitis B reactivation and current clinical impact. Rev Esp Enferm Dig 2010;102:542-552.
40. Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011;46:9-16.
41. Droz N, Gilardin L, Cacoub P, Berenbaum F, Wendling D, Godeau B, et al. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (Hoboken) 2013;65:1504-1514.
42. Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncology 2011;29:3270-3277.
43. Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012;30:3167-3173.